ArticleBMC neurology2026
Intravenous immunoglobulin frequency in multifocal motor neuropathy: a retrospective study of nerve conduction outcomes.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn resource-limited rural settings, patients with multifocal motor neuropathy (MMN) often present late due to limited access to neurophysiology services, by which time significant axonal damage may have occurred, rendering them less responsive to immunotherapy-yet this clinically subgroup is consistently underrepresented in randomized controlled trials. In this study, we aimed to examined the impact of intravenous immunoglobulin (IVIg) frequency on electrophysiological changes in such undertreated MMN patients.
methodsA retrospective analysis was conducted across three rural medical centers. Patients receiving > 2 IVIg cycles annually were classified as group A, others as group B. Nerve conduction was assessed at baseline, after the first treatment course, and at the final follow-up.
resultsThirty-nine MMN patients initially identified, 11 patients with confirmed conduction block (CB) were included. 27 nerves exhibited definite CB, with 7 (25.9%) in the median nerve, 8 (29.6%) in the ulnar nerve, and 6 (18.5%) in both the tibial and peroneal nerves. The treatment intervals was 4.9 ± 1.8 (range, 2.6 to 8.0) months, The follow-up period was 17.2 ± 3.3 months (range, 12.0 to 21.0). 7 (63.6%) were in group A, while 4 patients (36.4%) were in group B. There was a clear improvement in mRS scores at the last follow-up compared to baseline (z = -2.795, p = 0.007). We compared the variations in distal compound muscle action potential (CMAP) amplitude at baseline and the last follow-up, after adjusting for baseline CMAP amplitude, it showed significantly greater improvements in distal CMAP amplitude in group A versus group B (F = 40.217, P < 0.001; B = 2.881, 95% CI 1.941 ~ 3.821, P < 0.001), with the model accounting for 71.5% of the variance (adjusted R²= 0.715). The number of CBs decreased from 17 to 14 in group A, with no change in group B (p > 0.05).
conclusionsHigh frequency IVIg treatment may be associated with improved CMAP amplitude and mRS in undertreated MMN patients, suggesting potential benefits that require further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.